Home > Insider Trading > Filing (0001209191-17-066692)

Filing Details

Accession Number:: 0001209191-17-066692
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-12-20 19:48:14
Reporting Period:: 2017-12-18

Accepted Time:: 2017-12-20 19:48:14
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1649989	Oncobiologics Inc.	ONS	Biological Products, (No Disgnostic Substances) (2836)	383982704

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1663252	A. Elizabeth Yamashita	C/O Oncobiologics, Inc. 7 Clarke Drive Cranbury NJ 08512	Vp, Regulatory Affairs	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2017-12-18	1,509	$1.17	86,969	No	4	S	Direct
Common Stock	Disposition	2017-12-19	6,151	$1.14	80,818	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Footnotes

Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units ("RSUs"). This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.12 - $1.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
Includes shares of common stock underlying RSUs reported on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on December 22, 2016. The vesting of RSUs was accelerated such that 100% of the shares underlying the RSU will vest on December 21, 2017.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.11 - $1.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4.